Miami, FL (April 14, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into an agreement with Oklahoma State University to evaluate ZofinTM for the treatment of respiratory diseases caused by virus infections of pandemic potential. This study site follows the Company’s earlier announcement of the agreement reached with the Centers for Disease Control and Prevention (“CDC”) to conduct research to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection. [Read more…]
Shoreline Biosciences Raises $43M to Advance iPSC-derived Cellular Immunotherapies
Shoreline Biosciences, a California-based start-up specializing in iPSC-derived cellular immunotherapies for cancer and other serious diseases, announced it has completed an impressive $43M funding round. Founded in 2020 in La Jolla, CA, the company is developing a pipeline of induced pluripotent stem cell (iPSC) derived NK cell and macrophage cell therapy product candidates. The company joins an impressive list of pioneers who are now forging the path toward iPSC-derived cell therapeutics. [Read more…]
NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from US Patent Office
April 12, 2021, Baltimore, Maryland – NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: US 10.967,007 B2 “Cardiac Stem Cells for Cardiac Repair”. The innovation was developed by Dr. Sunjay Kaushal, a pediatric cardiac surgeon, while he was at the University of Maryland, Baltimore and NeoProgen is the exclusive licensee of the newly issued patent. [Read more…]
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19
Golden, Colorado-April 6, 2021 — Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Our Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19. [Read more…]
5 Reasons to Use Biological Industries’ NutriStem® for Isolation and Growth of hMSCs
Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells present in a variety of tissue niches within the human body. As multipotent cells, they can differentiate into a range of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. [Read more…]
- « Previous Page
- 1
- …
- 169
- 170
- 171
- 172
- 173
- …
- 338
- Next Page »